GSK-Genmab's leukemia drug Arzerra hits main goal in trial

05/30/2013 | RTT News

Genmab and GlaxoSmithKline's Arzerra, or ofatumumab, in combination with chlorambucil, achieved the primary goal of a late-stage trial by extending progression-free survival in patients with previously untreated chronic lymphocytic leukemia, a review found. Patients who took Arzerra survived 9.3 months longer without their disease worsening compared with patients who received chlorambucil alone.

View Full Article in:

RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Customer Service Director
Minneapolis, MN
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Behavioral Health Operations Director
Minneapolis, MN
President/Chief Executive Officer
Winston-Salem, NC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID